Welcome to Beike Biotech
Beike Biotechnology is a leading biotechnology company whose scientists have been dedicated to the development and commercialization of adult stem cell therapies since 1999. The company currently produces a full line of stem cell products derived from umbilical cord, cord blood, and bone marrow stem cells. Beike's proprietary processing and quality assurance technologies prepare the cells for use in treating a variety of serious medical conditions including ataxia, brain injury, cerebral palsy, diabetic foot disease, lower limb ischemia, multiple sclerosis, muscular dystrophy, spinal cord injury, and optic nerve damage.
Watch the video introduction to the Shenzhen Beike Biotechnology Company.
Beike's stem cells are derived from healthy donors who are carefully screened for transmissible diseases. The samples are additionally screened by government appointed blood banks and Beike’s specialized laboratories. The stem cells are then banked in state-of-the-art facilities and only utilized in partnership with the best hospitals and physicians.
Beike Earns AABB Accreditation for Cord Blood and Cord Tissue Banking
Beike Becomes China's First and Only AABB Accredited Stem Cell Bank and Sets High Industry Benchmarks for Stem Cell Application in China
SHENZHEN, China, May 29, 2012 /PRNewswire-Asia/ -- Beike Biotechnology Co., Ltd ("Beike") announced that it has been awarded AABB accreditation for cord blood and cord tissue banking. This accreditation has been granted following an intensive on-site assessment by AABB assessors and establishes that the level of medical, technical and administrative performance within the facility is in accordance with the AABB standards or exceeds those set by AABB. With this achievement, Beike becomes China's first and only AABB-accredited stem cell bank for both cord blood and cord tissue banking.
ThermoGenesis Announces AABB Accreditation for Beike Biotech
RANCHO CORDOVA, Calif., March 29, 2012 /PRNewswire/ -- ThermoGenesis Corp. (NASDAQ: KOOL), a leading supplier of innovative products and services that process and store adult stem cells, said today that its customer Beike Biotechnology Co., Ltd. (Beike) has become the first company in China to receive accreditation from the AABB (formerly the American Association of Blood Banks). AABB is an international, not-for-profit association representing nearly 2,000 institutions and 8,000 individuals involved in the fields of transfusion medicine and cellular therapies.
A leading stem cell and regenerative medicine company in China, Beike will be using ThermoGenesis' AXP® AutoXpress® (AXP) and BioArchive® Systems for the processing and storage of stem cells from cord blood. The Company expects the AXP device to receive registration approval in China during the current year.
New Study Finds Cord Blood-derived Stem Cell Treatments Improve Ataxia Patients' Functionality and Quality of LifeIn an Open Label Treatment Study 30 Patients with the Neurodegenerative Disorder Hereditary Ataxia Were Treated with Stem Cells Provided by Beike Biotechnology
SHENZHEN, China and SAN DIEGO, Calif., Sept. 6, 2011 /PRNewswire-Asia/ -- The Journal of Translational Medicine reports on a new study in which 30 patients with Hereditary Ataxia showed statistically significant improvements in functionality and quality of life after being treated with a combination of cord blood-derived stem cell treatments and physical therapy.
The study was conducted at the Nanshan Affiliated Hospital of Guangdong Medical College in China, and included the participation of Beike Biotechnology Company (http://www.beikebiotech.com/), China's leading stem cell research and regenerative medicine company, and the San Diego biotech company Medistem, Inc. (MEDS.PK). The peer-reviewed article is available at:http://www.translational-medicine.com/content/9/1/65.
Beike Biotechnology Upgrades Its Processing and Cryopreservation Technology to Expedite Advancements in Stem Cell Therapies
Beike and ThermoGenesis Intend to Establish a "Center of Excellence" Showcase in Taizhou City
TAIZHOU, China, March 16, 2011 /PRNewswire-Asia/ -- Beike Biotechnology Co. Ltd. ("Beike") (http://www.beikebiotech.com), China's leading stem cell research and regenerative medicine company, announced an agreement with USA-based ThermoGenesis Corp. to employ new, cutting edge stem cell processing and storage technology across its adult stem cell collection, processing, and archive platform.
Under the arrangement, which underscores Beike's strategic commitment to upgrading its current technology and clinical research capabilities, Beike becomes the first company in the People's Republic of China to secure the rights to the AXP and BioArchive Cord Blood systems. AXP® is a proprietary family of automated devices used for the processing of cord blood; the BioArchive® System is an automated cryogenic device used to archive cord blood stem cell units for transplant.
- New Research Demonstrates Safety of Cord-blood-derived Stem Cell Treatments
- New Study Demonstrates Improvements in Lupus Patients Receiving Stem Cell Therapies
- Beike Biotechnology Opens First Chinese Rehabilitation Center in Romania
- Beike Biotech Launches New International Stem Cell Venture
- Beike Biotechnology Opens World's Largest Stem Cell Storage and Processing Facility
- Beike Biotechnology Receives International Recognition for Quality Control Processes